Category: biotech

.Only a handful of brief full weeks after succeeding an FDA Fast Track tag for its own investigational BTK degrader in specific blood cancers cells,

.AbbVie has actually gone back to the resource of its antipsychotic goliath Vraylar looking for one more hit, spending $25 thousand in advance to create

.On the same time that some Parkinson’s ailment medications are being cast doubt on, AbbVie has revealed that its late-stage monotherapy applicant has actually substantially

.AstraZeneca has actually utilized artificial intelligence to create a special biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), wishing to differentiate the antibody-drug conjugate

.Monopar Rehabs is actually bouncing back a medication from the scrap heap of AstraZeneca’s unusual illness pipeline. It has actually licensed ALXN-1840, an applicant for